Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older. It is available as tablets and oral suspension. MedsAcross supplies Deflazacort for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
EMFLAZA is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older. EMFLAZA is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older
Source: US FDA prescribing information
Deflazacort is a corticosteroid prodrug, whose active metabolite, 21-desDFZ, acts through the glucocorticoid receptor to exert anti-inflammatory and immunosuppressive effects. The precise mechanism by which deflazacort exerts its therapeutic effects in patients with DMD is unknown.
Source: US FDA prescribing information
The recommended once-daily dosage is approximately 0.9 mg/kg/day administered orally. Discontinue gradually when administered for more than a few days
Source: US FDA prescribing information
EMFLAZA is contraindicated in patients with known hypersensitivity to deflazacort or to any of the inactive ingredients. Instances of hypersensitivity, including anaphylaxis, have occurred in patients receiving corticosteroid therapy. Hypersensitivity to deflazacort or any of the inactive ingredients in EMFLAZA
Source: US FDA prescribing information
Alterations in Endocrine Function: Hypothalamic-pituitary-adrenal axis suppression, Cushing’s syndrome, and hyperglycemia can occur, Monitor patients for these conditions with chronic use of EMFLAZA. Immunosuppression and Increased Risk of Infection: Increased risk of new, exacerbation, dissemination, or reactivation of latent infections, which can be severe and at times fatal, Signs and symptoms of infection may be masked. Alterations in Cardiovascular/Renal Function: Monitor for elevated blood pressure and sodium, and for decreased potassium levels. Gastrointestinal Perforation: Increased risk in patients with certain GI disorders, Signs and symptoms may be masked. Behavioral and Mood Disturbances: May include euphoria, insomnia, mood swings, personality changes, severe depression, and psychosis.
Source: US FDA prescribing information
The following serious adverse reactions are discussed in more detail in other sections: Alterations in Endocrine Function Immunosuppression and Increased Risk of Infection Alterations in Cardiovascular/Renal Function Gastrointestinal Perforation Behavioral and Mood Disturbances Effects on Bones Ophthalmic Effects Immunizations Serious Skin Rashes Effects on Growth and Development Myopathy Kaposi’s Sarcoma Risk of Serious Adverse Reactions in Infants because of Benzyl Alcohol Preservative Thromboembolic Events Anaphylaxis The most common adverse reactions (≥ 10% for EMFLAZA and greater than placebo) are Cushingoid appearance, weight increased, increased appetite, upper respiratory tract infection, cough, pollakiuria, hirsutism, central obesity, and nasopharyngitis
Source: US FDA prescribing information
Moderate or strong CYP3A4 inhibitors: Give one third of the recommended dosage of EMFLAZA. Avoid use of moderate or strong CYP3A4 inducers with EMFLAZA, as they may reduce efficacy
Source: US FDA prescribing information
Store at 20°C to 25°C (68°F to 77°F). Excursion permitted between 15°C to 30°C (59°F to 86°F). See USP controlled room temperature.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
21 presentations of Deflazacort, sorted by availability.
5 brand names across 1 markets.
United States
Indian manufacturers are highlighted.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 9 February 2017 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Deflazacort in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 21 presentations of Deflazacort and sources them for licensed hospitals, importers and physicians against valid import documents. Indian manufacturers include Zydus Lifesciences.
The catalogue lists 5 brand names for Deflazacort, including Emflaza, Jaythari, JAYTHARI Oral Suspension, Kymbee, Pyquvi.
Yes. The US FDA first approved Deflazacort on 9 February 2017, according to Drugs@FDA.
No listed presentation of Deflazacort is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Deflazacort is classified under ATC code H02AB13 (Deflazacort).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.